Neutralizing antibodies against SARS-CoV-2 variants following mRNA booster vaccination in adults older than 65 years

Durier, Christine; Ninove, Laëtitia; Lefèbvre, M.; Radenne, Anne; Desaint, Corinne; Ropers, Jacques; Bauer, Rebecca; Carette, Diane; Lachâtre, Marie; Lecompte, Anne-Sophie; Deplanque, Dominique; Botelho-Nevers, Élisabeth; Conrad, Anne; Maakaroun-Vermesse, Zoha; Nicolas, Jean-François; Verdon, Renaud; Kiladjian, Jacques; Loubet, Paul; Schmidt-Mutter, Catherine; Dualé, Christian; Ansart, Séverine; Priet, Stéphane; Levier, Axel; Molino, Diana; Vieillard, Louis-Victorien; Lelièvre, Jean‐Daniel; Lamballerie, Xavier De; Launay, Odile; Imbert-Marcille, Berthe-Marie; Montagne, Samantha; Traverse-Gléhen, Alexandra; Vivien, Denis; Cassinat, Bruno; Evrard, Alexandre; Metzger, Catherine; Lessinger, Jean‐Marc; Billing, Michel; Berger, Marc; Leroyer, Christophe; Tartour, Éric; Pellegrin, Isabelle; Éloit, Marc; Resch, Martine; Mestre, Soizic Le; Jancrey-Laval, Solange; Rosenthal, Éric; Yazdanpanah, Yazdan; Olive, Daniel; Tardieu, Raphaelle; Petrov–Sanchez, Ventzislava; Bouakane, Amel; Rieux, Véronique; Madelaine, Claire; Lemestre, Soizic; Diallo, Alpha Oumar Karim; Lancrey-Javal, Solange; Meyer, Laurence; Netzer, Emmanuelle; Saouzanet, Marine; Dussol, Bertrand; Melica, Giovanna; Mchantaf, Gilbert; Hisbergues, Michael; Bertholon, Frédérique; Icard, Vinca; Sandre-Giovannoli, Annachiara De; Ghaleh-Marzban, Bijan; Eberhardt, Christiane; Dropy, Margot; Bouchama, Fatiha; Thamri, Mehdi; Lebbah, Saïd; Bonneton, Marion; Azimi, Shorheh; Parfait, Béatrice; Appay, Victor; Batteux, Frédéric; Combadière, Béhazine; Gorochov, Guy; Paul, Stéphane; Werf, Sylvie van der; Siegrist, Claire‐Anne; Cogné, Michel; Valour, Florent

doi:10.1038/s41598-022-24409-w

Cited by 5 publications

(3 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We show here that this level, possibly a plateau, was reached after two doses in naïve younger people, while three doses were required in naïve NH residents. This is not very different from other published data showing similar or only slightly higher total IgG titres post D3 versus D2 while observing more significant gains in neutralization capacity, amongst others [23] , [25] .…”

Section: Discussioncontrasting

confidence: 68%

Third dose of COVID-19 mRNA vaccine closes the gap in immune response between naïve nursing home residents and healthy adults

Pannus¹,

Depickère²,

Kemlin³

et al. 2023

Vaccine

View full text Add to dashboard Cite

Section: Discussioncontrasting

confidence: 68%

Third dose of COVID-19 mRNA vaccine closes the gap in immune response between naïve nursing home residents and healthy adults

Pannus¹,

Depickère²,

Kemlin³

et al. 2023

Vaccine

View full text Add to dashboard Cite

“…Серьезных нежелательных явлений не зарегистрировано. Побочные проявления после вакцинации отличались непродолжительностью, нестойкостью и полным исчезновением в первые 1-2 суток после их развития и не оказали негативного влияния на течение хронического заболевания [53,[64][65][66][67][68][69][70][71][72][73][74][75].…”

Section: Discussionunclassified

Prognostic Factors Associated with the Severe Course of a New Coronavirus Infection

Khamanova,

Frayfeld,

Mullagalieva

et al. 2024

Урал. мед. журнал

View full text Add to dashboard Cite

Introduction. Novel coronavirus infection (COVID-19) is a respiratory infectious disease caused by the novel severe acute respiratory syndrome 2 coronavirus (SARS-CoV-2). It is characterized by a heterogeneous course of the disease from asymptomatic and mild forms to more severe and fatal outcomes. There are many risk factors for a severe course of a new coronavirus infection, in most cases, a severe course of the disease is associated with the individual characteristics of the patient, especially with dysregulation of the immune response. In this article, we reviewed the main prognostic factors for the severity of the disease.The aim of the study is to determine the unfavorable prognostic factors associated with the severe course of a new coronavirus infection caused by the SARS-CoV-2 virus in foreign and domestic literature sources.Materials and methods. To achieve this goal, scientific publications on the new coronavirus infection caused by the SARS-CoV-2 virus were analyzed in the scientometric databases PubMed, National Center for Biotechnological Information (NCBI), Cochrane, Web of Science, Scopus, MEDLINE (2019–2022), and Russian specialized journals on infectious diseases (2019–2022). Particular attention was paid to factors influencing the severe course of a new coronavirus infection.Results. Risk factors for a severe course of a new coronavirus infection include: lipid spectrum, advanced age, hemostasis system, changes in the leukocyte count, serum markers. Mathematical models of the course of a new coronavirus infection have also been developed.Discussion. In most studies, scientists note that the uncontrolled course of COVID-19 disease is associated with a dysregulated immune response. One of the main methods of influencing the immune system is vaccination.Conclusion. There are many factors that contribute to the development of severe forms of the disease of a new coronavirus infection. However, thanks to universal vaccination against a new coronavirus infection, the frequency of severe forms of the disease and deaths has significantly decreased. Novel coronavirus infection (COVID-19) is a respiratory infectious disease caused by the novel severe acute respiratory syndrome 2 coronavirus (SARS-CoV-2).

show abstract

“…In fact, the median age at vaccination in this study was 54 years, while that in the previous study was 61 years. Despite the differences in age categories and the timing of post-vaccination measurement of antibody titers in various studies [ 24 , 25 , 26 , 27 ], they all suggest that acquiring antibodies with increasing age is challenging. Although we did not find any difference in age between patients with and without antibody acquisition, and we cannot make direct comparisons with previous literature, we speculate that age may have a bias in the rate of antibody acquisition.…”

Section: Discussionmentioning

confidence: 99%

Assessment of Antibody-Titer Changes after Second and Third Severe Acute Respiratory Syndrome Coronavirus 2 mRNA Vaccination in Japanese Post-Kidney-Transplant Patients

Fujieda

Tanaka²,

Kikuchi³

et al. 2023

Vaccines

View full text Add to dashboard Cite

Post-renal-transplant patients have a relatively low antibody-acquisition rate following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA vaccination. In this study, antibody titers were measured 5–6 months and 3 weeks to 3 months after the second and third SARS-CoV-2 mRNA vaccinations, respectively. Post-renal-transplant patients visiting our hospital who had received three SARS-CoV-2 mRNA vaccine doses were included in the study. SARS-CoV-2 immunoglobulin G antibody titers were measured three times: between 3 weeks and 3 months after the second vaccination, 5–6 months after the second vaccination, and between 3 weeks and 3 months after the third vaccination. A total of 62 (40 men and 22 women) were included, 44 of whom (71.0%) were antibody positive after their third vaccination. On comparing the antibody-acquired and antibody-non-acquired groups, body mass index (BMI, odds ratio [OR]: 1.44, 95% confidence interval [CI]: 1.07–1.93, p < 0.05) and the estimated glomerular filtration rate (eGFR, OR: 1.14, 95% CI: 1.06–1.24, p < 0.01) were associated with antibody acquisition. Therefore, in Japanese post-kidney-transplant patients, increases in the antibody-acquisition rate and absolute antibody titer after the third vaccination were observed, with BMI and eGFR associated with the antibody-acquisition rate.

show abstract

Neutralizing antibodies against SARS-CoV-2 variants following mRNA booster vaccination in adults older than 65 years

Cited by 5 publications

References 27 publications

Third dose of COVID-19 mRNA vaccine closes the gap in immune response between naïve nursing home residents and healthy adults

Third dose of COVID-19 mRNA vaccine closes the gap in immune response between naïve nursing home residents and healthy adults

Prognostic Factors Associated with the Severe Course of a New Coronavirus Infection

Assessment of Antibody-Titer Changes after Second and Third Severe Acute Respiratory Syndrome Coronavirus 2 mRNA Vaccination in Japanese Post-Kidney-Transplant Patients

Contact Info

Product

Resources

About